Scientific article
OA Policy
English

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients

Published inBlood advances, vol. 6, no. 17, p. 4975-4982
Publication date2022-09-13
First online date2022-06-24
Abstract

Background: COVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE).

Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for patients with COVID-19.

Methods: ASH formed a multidisciplinary guideline panel, including 3 patient representatives, and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing systematic evidence reviews (up to January 2022). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 and May 2021 as part of the living phase of these guidelines.

Results: The panel made 1 additional recommendation: a conditional recommendation for the use of prophylactic-intensity over therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of thrombotic and bleeding risk.

Conclusions: This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation for patients with COVID-19-related critical illness.

Keywords
  • Anticoagulants / therapeutic use
  • COVID-19
  • Critical Illness / therapy
  • Hematology
  • Humans
  • United States
  • Venous Thromboembolism / drug therapy
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / prevention & control
Funding
  • NHLBI NIH HHS - [K01 HL135466]
Citation (ISO format)
CUKER, Adam et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. In: Blood advances, 2022, vol. 6, n° 17, p. 4975–4982. doi: 10.1182/bloodadvances.2022007940
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal2473-9529
101views
21downloads

Technical informations

Creation09/13/2022 1:53:00 PM
First validation09/13/2022 1:53:00 PM
Update time03/16/2023 10:50:27 AM
Status update03/16/2023 10:50:26 AM
Last indexation11/01/2024 4:20:29 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack